RNS Number : 6656J
ValiRx PLC
25 August 2021

25 August 2021

ValiRx Plc

("ValiRx" or the "Company")

Appointment of Broker

ValiRx Plc (AIM: VAL), has appointed Cenkos Securities plc ("Cenkos") as its sole broker with immediate effect.

In connection with the appointment of Cenkos, the Company has granted Cenkos with a warrant over 3,902,949 ordinary shares in the Company exercisable at price of 22p, being the closing mid-price on 24 August 2021 ("Warrants"). The Warrants are exercisable in whole or in part for the period commencing 12 months after the commencement of their engagement and ending 60 months after their engagement.

Dr Kevin Cox, Chairman commented: "We are very much looking forward to working closely with the Cenkos growth companies team to help deliver and further develop the strategy we have been building over the last year. After a period of consolidation and stability, this is a natural evolution in our growth plans."

ValiRx plc **Tel: +44 (0) 2476 796496**

www.valirx.com
Suzanne Dilly, CEO Suzanne.Dilly@valirx.com

Cairn Financial Advisers LLP (Nominated Adviser) **Tel: +44 (0) 20 7213 088**

Liam Murray / Jo Turner / Ludovico Lazzaretti

Cenkos Securities Plc (Broker) **Tel: +44 (0)20 7397 8900**

Russell Kerr/Michael Johnson (Sales)

Callum Davidson/Giles Balleny (Corporate finance)

About ValiRx plc

ValiRx accelerates the development of treatments in oncology and women's health to improve patient lives. We provide the scientific, financial and commercial framework towards enabling rapid translation of innovative science into clinical development.

With our extensive and proven experience in research and drug development, we select and incubate promising novel drug candidates and guide them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

Integrating science and business

We connect diverse disciplines across scientific, technical and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. We work closely with our selected collaborators and leverage the combined expertise required for science to advance.

Lead candidates from our portfolio are out-licensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation. https://www.valirx.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

APPDKQBQOBKDFFB